Navigation Links
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Date:10/15/2007

ANN ARBOR, Mich., Oct. 15 /PRNewswire/ -- Velcura Therapeutics, Inc. has named Jeffrey N. Fellows, a biotechnology regulatory executive with more than 20 years of successful regulatory experience, as Vice President of Regulatory Affairs.

Velcura Therapeutics President and CEO Michael W. Long, PhD, said, "Jeff is a great addition to our senior management team. He will be responsible for our clinical trials applications, regulatory compliance and interactions with the Federal Drug Administration. His more than two decades of experience will be critical in helping Velcura navigate the regulatory path for VEL-0230, our new drug that stimulates bone formation and inhibits bone loss." Dr. Long added, "Jeff's past experience with the Oncology Division at FDA is a definite plus as our initial clinical trial of VEL-0230 in patients will be for treatment for Multiple Myeloma Bone Disease, a blood cancer associated with profound bone loss."

Immediately before joining Velcura Therapeutics, Fellows was Vice President of Regulatory Affairs for Cell Therapeutics, Inc. in Seattle, where for the past three years he was the main liaison with the FDA and responsible for the development of global regulatory strategy and agency filings for the oncology focused company.

Prior to CTI, Fellows worked for Amgen Inc. in Thousand Oaks, CA, and worked in a series of increasingly responsible positions, eventually serving as Director of Regulatory Affairs and Global Regulatory Team Leader in Thousand Oaks, California. There Fellows served on Corporate Global Product Strategy Teams for early- and late-stage development compounds and led Global Regulatory Teams in the United States, Europe, Canada, Australia, and Japan.

After graduation from Oregon State University with a Bachelor of Science in Microbiology, Fellows began his career in regulatory affairs at NeoRx Corporation, where he prepared Investigational New Drug Applications for anti- cancer products. He worked for Synergen, Inc. in Boulder, Colorado, from 1990 until Amgen purchased Synergen in late 1994.

Jeffery Fellows lives in Woodway, Washington, and will work from Velcura's Seattle office.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics, Inc. is an early-stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti- bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, ... executives and entrepreneurs, held The Future of San Diego Life Science event at the ... life science community attended the event with speakers Dr. Rich Heyman, former CEO of ...
(Date:5/23/2016)... Willoughby, Ohio (PRWEB) , ... May 23, 2016 ... ... Six Trends That Will Drive Precision Farming in 2017 and Beyond. The paper ... and practitioners in the precision ag industry. , “We’ve witnessed a lot of ...
(Date:5/23/2016)... , May 23, 2016 - Leading ... 40% - Frontage Implement a Single Platform to Manage ... and Traceability Within the Bioanalytical lab Frontage Laboratories, a ... United States and China , has ... laboratory facilities. In addition to serving as the global electronic lab ...
Breaking Biology Technology:
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/11/2016)... March 11, 2016 http://www.apimages.com ) - ... Picture is available at AP Images ( http://www.apimages.com ) - ... be used to produce the new refugee identity cards. DERMALOG will ... at CeBIT in Hanover next week.   ... will be used to produce the new refugee identity cards. DERMALOG ...
Breaking Biology News(10 mins):